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Abstract
This study presents enhanced surveillance data from 2004 to 2018 for all community-asso-
ciated methicillin-resistant Staphylococcus aureus (CA-MRSA) specimens collected in
Western Australia (WA), and describes the changing epidemiology over this period. A total
of 57 557 cases were reviewed. Annual incidence rates increased from 86.2 cases per 100
000 population to 245.6 per 100 000 population (IRR = 2.9, CI95 2.7–3.0). The proportion
of isolates carrying Panton–Valentine leucocidin (PVL)-associated genes increased from
3.4% to 59.8% (χ2 test for trend 7021.9, P < 0.001). The emergence of PVL-positive,
‘Queensland CA-MRSA’ (ST93-IV) and ‘WA 121’ (ST5-IV) accounted for the majority of
increases in CA-MRSA across the study period. It is unclear why some clones are more prolific
in certain regions. In WA, CA-MRSA rates increase as indices of temperature and humidity
increase after controlling for socioeconomic disadvantage. We suggest climatic conditions may
contribute to transmission, along with other socio-behavioural factors. A better understanding
of the ability for certain clones to form ecological niches and cause outbreaks is required.
Background
Staphylococcus aureus is the most commonly isolated bacterial pathogen in humans and is
an important cause of skin and soft-tissue infections (SSTIs), pneumonia, septic arthritis,
endocarditis, osteomyelitis, foreign-body infections and sepsis [1]. Methicillin-resistant S.
aureus (MRSA) isolates are resistant to penicillins and other β-lactam antibiotics and in
the past were confined mainly to health care environments [2]. However, over the last
30 years, there has been an increase in the number of MRSA infections in persons with-
out the usual healthcare-associated risk factors. An increased recognition of new MRSA
clones, commonly referred to as community-associated MRSA (CA-MRSA) in order to
distinguish them from their healthcare-associated counterparts, is responsible for such
infections [2].
In Australia, CA-MRSA infections first emerged from the northern Kimberley region in
Western Australia (WA) in the early 1990s, mainly associated with Aboriginal people living
in remote communities [3]. Since that time, the heavy burden of staphylococcal disease and
an increasing prevalence of CA-MRSA in these populations across northern Australia have
been noted [4].
Different CA-MRSA strains have been demonstrated to have found ecological niches, with
different regions experiencing outbreaks largely comprising different dominant strains [1],
such as USA300 in North America, ST80-IV ‘European clone’ in countries of the Gulf
Cooperation Council [5], the ST30-IV ‘South Western Pacific clone’ in New Zealand [2].
While the global emergence and spread of CA-MRSA have previously been well-documented
[6], Australia has been no exception [7], with ST93-IV ‘Queensland CA-MRSA’ noted as the
predominant clone in Australia for over a decade [8].
Western Australia has adopted an aggressive approach to MRSA management, with strin-
gent policy requirements for the screening, reporting and management of cases introduced in
the 1980s [9]. Colonisation or infection with MRSA has been a notifiable condition in WA
since 1982, and since 1997 all MRSA isolates have been referred to the PathWest
Gram-positive typing Laboratory (GPTL) where isolates are characterised as either
healthcare-associated MRSA (HA-MRSA) or CA-MRSA based on molecular markers [10].
Since 2003, GPTL has employed multilocus sequence typing (MLST) and staphylococcal
chromosomal cassette mec (SCCmec) typing which has enabled the identification of novel
clones not previously reported. This study presents 15 years of enhanced surveillance data
from specimens collected in WA, and describes the changing epidemiology and burden of
disease over this period.
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CA-MRSA and HA-MRSA
Phenotypically, CA-MRSA clones are generally resistant to fewer
non-β-lactam antibiotics than HA-MRSA clones [11]. Clinically,
CA-MRSA infections generally occur in younger, otherwise
healthy patients and are associated predominantly with SSTIs,
but may also cause severe clinical syndromes such as necrotizing
pneumonia and sepsis [1, 12]
In WA, CA-MRSA clones are frequently responsible for infec-
tions detected in the hospital setting, including those classified as
nosocomial infections [13]. Consequently, classification of
CA-MRSA and HA-MRSA clones based solely on hospitalisation
and risk factors for healthcare may lead to frequent differential
misclassification [11] with molecular typing methods considered
a more accurate means of identifying and classifying CA-MRSA
clones.
CA-MRSA may be differentiated from HA-MRSA clones by
genotypic features such as MLST, having a relatively smaller
SCCmec elements (typically type IV and V), and by the frequent
presence of the Panton–Valentine leucocidin (PVL) lukF-PV and
lukS-PV associated genes [11]. Typing data from GPTL are used
to direct patient management and appropriate infection control
responses within WA healthcare facilities.
PVL status
The protein coded by the lukF-PV and lukS-PV PVL-associated
genes mediates leukocyte and tissue destruction, and it has been
suggested that its presence may cause more severe SSTIs than
PVL-negative (PVL−) isolates [12, 14]. However, controversy
remains regarding whether observed increases in disease severity
are due to the presence of the PVL toxin, or if it is a marker
for other virulence factors [1]. Conflicting evidence from animal
and human studies has led to inconclusive findings of the exact
role of PVL in disease severity; however, evidence suggests that
the effects may be strain-specific [1].
Although PVL-positive (PVL+) isolates do not appear to be
related to increases in bacteraemia or mortality [12], a demon-
strated propensity to cause more invasive SSTIs would place a sig-
nificant burden on healthcare services if the incidence of these
strains increased, with more complex procedures required to
treat and manage these infections.
Methods
Genotyping
In WA, the classification of CA-MRSA and HA-MRSA clones is
determined by a combination of the molecular analysis of the
seven housekeeping genes sequence types using MLST, and the
SCCmec type using multiplex PCR [15]. Prior to 2014, all
CA-MRSA (regardless of PVL status) wereindividually typed.
Increases in case numbers and subsequent workload, combined
with the low applicability of the results to patient management,
led to a decision to group all PVL− CA-MRSA under one typing
result. This classification was applied retrospectively to all data,
and therefore all PVL− CA-MRSA are grouped together.
Typing data for PVL+ isolates are available for the full study
period.
Epidemiology
Cases were extracted with the following inclusion criteria:
• Collection date between 1 January 2004 and 31 December 2018
• Persons with a WA address (classified by residential postcode)
at the time a sample was collected
• Sample was positive for a CA-MRSA clone identified by GPTL
• Sample was identified as a clinical specimen (screening speci-
mens excluded)
• Specimen was not a duplicate (specimen of the same strain
collected from the same patient)
Fig. 1. Regions and climatic zones, Western Australia, adapted from Bureau of Meteorology [18].
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Estimated resident population (ERP) figures from 2004 to
2017 were obtained from the Australian Bureau of Statistics for
each region. Regional ERP for 2018 was estimated based on linear
population growth trends for the period 2015–2017.
Study population
WA comprises approximately 2.6 million km2 and is commonly
divided into eight major geographical regions. Each of these
regions varies widely on a number of factors, including geography
and climate, population density, proportion of Aboriginal resi-
dents, and indices of rurality and remoteness. Regional areas of
the state, particularly northern and easterly regions, contain
populations with some of the highest indices of socio-economic
disadvantage in Australia [16]. The population of WA is approxi-
mately 2.6 million people, with almost three-quarters of the popu-
lation residing in metropolitan Perth [17].
Regions were further categorised based on their climatic prop-
erties, using Bureau of Meteorology data for climate zones based
on temperature and humidity [18].
Regions were assigned to climate zones based on having a
majority of regional landmass and/or population within a particu-
lar band. Zone 1 (hot, humid summer) contained the northern-
most Kimberley region, Zone 3 (hot dry summer, mild winter)
contained the northern-central Pilbara and Midwest regions,
Zone 4 (hot dry summer, cold winter) contained the central
Wheatbelt and Goldfields regions, and Zone 5 (warm summer,
cold winter) contained the southerly Metropolitan, Southwest
and Great Southern regions (Fig. 1). Deciles taken from the
ABS Indices of Relative Socio-Economic Advantage and
Disadvantage (IRSAD) were applied based on patient postcode.
Statistical analysis
Data analysis was performed using R version 3.5.2 (R Foundation
for Statistical Computing; Vienna, Austria). Annual incidence
rates per 100 000 population were calculated. A Wilcoxon rank-
sum test was used to assess the difference in continuous variables.
Multivariable logistic regression was used to assess age, sex and
climatic region of residence as independent risk factors for PVL
+ CA-MRSA. Cases with missing data for sex and age group
were deleted listwise. Negative binomial regression models were
selected due to overdispersion of annual count data, and were
used to estimate year-adjusted regional incidence rate ratios
(IRRs) and associated 95% confidence intervals (CI95).
Results
A total of 57 557 cases of CA-MRSA reported to GPTL between
1 January 2004 and 31 December 2018 were extracted from the
database in January 2019. While overall, the majority (57%) of
cases reported over the 15-year period were PVL− CA-MRSA,
assessment of annual trends demonstrates the proportion of
PVL+ CA-MRSA increased from 3.4% to 59.8%, comprising
the majority of isolates since 2015 (χ2 test for trend 7021.9,
P < 0.0001) (Table 1).
Incidence rates by climatic region and PVL status
Between 2004 and 2018, annual incidence rates of CA-MRSA in
WA increased almost threefold, from 86.2 cases per 100 000
population to 245.6 per 100 000 population (IRR = 2.9, CI95
2.7–3.0). At the commencement of the monitoring period, there
were some differences noted in the incidence rates of
CA-MRSA in the hotter climatic zones, with significantly higher
total rates in Zone 1 (IRR = 3.2, CI95 2.5–3.9) and Zone 3
(IRR = 1.7, CI95 1.4–2.0) compared with the cooler Zone 5
Table 1. CA-MRSA cases, WA, 2004–2018
PVL negative
CA-MRSA
PVL positive
CA-MRSA Total
n (%) n (%) N
Total 32 868 (57.6%) 24 689 (42.4%) 57 557
Sex
Female 17 263 (60.4%) 11 464 (39.6%) 28 727
Male 15 540 (54.7%) 13 205 (45.3%) 28 745
Unknown 65 (76.5%) 20 (23.5%) 85
Year
2004 1649 (96.7%) 58 (3.3%) 1707
2005 1573 (94.1%) 101 (5.9%) 1674
2006 1693 (92%) 153 (8%) 1846
2007 1718 (83.8%) 356 (16.2%) 2074
2008 1916 (78.9%) 540 (21.1%) 2456
2009 2077 (75.8%) 712 (24.2%) 2789
2010 1933 (71.7%) 811 (28.3%) 2744
2011 2289 (67.6%) 1156 (32.4%) 3445
2012 2239 (62.5%) 1450 (37.5%) 3689
2013 2364 (56.1%) 2006 (43.9%) 4370
2014 2675 (51.8%) 2511 (48.2%) 5186
2015 2769 (46.2%) 3157 (53.8%) 5926
2016 2644 (42%) 3698 (58%) 6342
2017 2802 (40.3%) 4220 (59.7%) 7022
2018 2527 (41.2%) 3760 (58.8%) 6287
Age group
0–9 years 3891 (41.1%) 5380 (58.9%) 9271
10–19 years 2306 (34.9%) 4211 (65.1%) 6517
20–29 years 3025 (40%) 4442 (60%) 7467
30–39 years 3272 (45.4%) 3898 (54.6%) 7170
40–49 years 3145 (51.4%) 3013 (48.6%) 6158
50–59 years 3041 (61.6%) 1955 (38.4%) 4996
60–69 years 3225 (76.1%) 1024 (23.9%) 4249
70–79 years 3475 (89.4%) 431 (10.6%) 3906
80+ years 7475 (95.9%) 334 (4.1%) 8970
Unknown 13 (93.3%) 1 (6.7%) 14
Climate zone
Zone 1 2570 (28.4%) 6402 (71.6%) 8972
Zone 3 3579 (45.9%) 4264 (54.1%) 7843
Zone 4 2187 (55.8%) 1796 (44.2%) 3983
Zone 5 24 532 (67.4%) 12 227 (32.6%) 36 759
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(reference category) in the south of the state. The differences
noted at this time are entirely attributable to PVL− strains, with
very few cases of PVL+ CA-MRSA (n = 58) reported within the
state in 2004 (Fig. 2).
The IRR of all CA-MRSA increased significantly as indices of
temperature and humidity increased across climatic zones
(Table 2). After adjusting for year in the negative binomial
model, a trend was identified for both PVL− and PVL+
CA-MRSA. Using Zone 5 (warm summer, cold winter) as a refer-
ence, the IRR for all CA-MRSA was over ninefold higher in total
in the northerly region of the state (Zone 1), compared to the ref-
erence (Zone 5).
The median age for PVL+ cases was significantly lower at 26.7
years, compared with 54.5 years for PVL− cases (P < 0.001).
Multivariable logistic regression adjusting for collection year
and IRSAD demonstrated that male sex, younger age, and resi-
dence in hotter, more humid regions were positively associated
with infection with PVL+ CA-MRSA, compared to other strains
(Table 3).
Molecular biology
The emergence of two PVL+ clones, ‘Queensland CA-MRSA’
(ST93-IV) and ‘WA121’ (ST5-IV), account for the majority of
increases in CA-MRSA across the study period. Proportionally,
Queensland CA-MRSA accounted for 1.6% of all CA-MRSA
strains in 2004; this increased to 37.9% of the total by 2018.
Case numbers for this clone increased across the state, and is
now the single most prolific strain in WA. As shown in
Figure 3, the case numbers of this clone are disproportionately
higher in Zone 1, which has comparable counts to Zone 5, despite
Zone 5 having a population approximately 66 times the size.
The emergence of WA121 occurred in 2011 with five cases of
this previously undetected clone occurring in this year. This
Fig. 2. Incidence rates, CA-MRSA, Western Australia, 2004–2018.
Table 2. Year-adjusted incidence rate ratios, by climate zone
PVL− CA-MRSA PVL+ CA-MRSA All CA-MRSA
Climate zone IRRa CI95 IRR
a CI95 IRR
a CI95
Zone 1 5.38 4.70 6.15 15.74 11.70 21.16 9.11 7.22 11.49
Zone 3 2.37 2.08 2.70 3.49 2.60 4.68 2.90 2.31 3.63
Zone 4 1.30 1.13 1.48 1.74 1.29 2.34 1.41 1.12 1.77
Zone 5 1.00 Ref 1.00 Ref 1.00 Ref
aAdjusted for year of specimen collection.
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number increased rapidly to 73 cases in 2012. Since this time,
year-on-year increases in WA121 have been observed, in 2018
accounted for 740/6287 (11.8%) of all reported CA-MRSA. The
same regions in which Queensland CA-MRSA has proliferated
again account the majority of increase in case numbers of WA121.
Greater diversity among PVL+ isolates is noted in the south-
erly, cooler, more densely populated regions, with South West
Pacific (SWP) CA-MRSA (ST30-IV) and the PVL+ ST22-IV
representing a sizeable minority within these zones. While PVL
− CA-MRSA rates increased overall during this period, propor-
tionally PVL− isolates declined from 97% of the total to 40%.
This demonstrates that rather than replacement, PVL+ isolates
have had an additive effect on the over rates of CA-MRSA in
WA over the last 15 years.
Discussion
This study reports a sustained increase in clinical CA-MRSA rates
in WA, with an apparent commencement of an outbreak of PVL+
MRSA in regional areas commencing 2009. Reports of increases
in CA-MRSA are occurring globally, including Europe, the
Asia-Pacific region and North America [1, 19, 20]. The introduc-
tion and proliferation of Queensland CA-MRSA in the last 15
years have dominated the landscape of CA-MRSA in WA, with
this clone alone accounting for almost 40% of all CA-MRSA
cases in the most recent reporting period.
In addition, the recent emergence of WA121 appears to follow
a similar pattern as the Queensland CA-MRSA, with a sudden
emergence and rapid proliferation in remote communities.
Given the demonstrated ability for a newly introduced clone to
add to the burden of disease in the community, the emergence
of a new PVL+ clone in these regions is of particular concern.
This same clone rapidly emerged in New Zealand between 2006
and 2011 [21] to become a dominant strain in that country during
this period.
The emergence and spread of CA-MRSA, particularly in the
Kimberley region, have previously been documented [9, 22]. The
precise reason for the emergence and spread of PVL+ strains dur-
ing this period is not currently known; however, a disproportionate
burden of PVL+ CA-MRSA among younger, Aboriginal
Australians is well established [7, 23–25]. Reasons for the increased
number of cases within these populations are complex, and centre
around environmental and behavioural determinants, such as
domestic overcrowding, comorbidities (especially the presence of
other skin conditions), hygiene and antibiotic use [23, 24].
Although Aboriginal status was not available as part of the dataset,
the increase in case numbers associated with regions and remote
areas with a high proportion of Aboriginal residents [26] suggests
that Aboriginal people are likely over-represented in these data.
Queensland CA-MRSA has previously been implicated as a
major contributor to the burden of disease in Aboriginal popula-
tions, suggesting particular genetic factors unique to this clone
may have facilitated its spread in this population across
Australia [24, 27]. The epidemiology of PVL+ USA300 within
North America mirrors the WA experience with Queensland
CA-MRSA in many ways – a rapid emergence and subsequent
dominance of a particular well-adapted clone [1], which is now
responsible for an increasing number of healthcare-associated
infections [28].
Despite numerous incursions of USA300 observed over the
surveillance period, this strain has not proliferated in WA.
Similarly, despite small-scale outbreaks of Queensland
CA-MRSA in the UK [29], it has not resulted in the same wide-
spread dissemination in this country [1]. In fact, this clone has
had apparently very limited spread, even within the Asia-Pacific
region [19]. Reasons why some strains seem to dominate in cer-
tain regions and not others remain unclear; however, this suggests
that there are other factors, outside of a susceptible population
and apparently fit strain, which allow establishment and transmis-
sion in a certain region.
The rate of PVL+ CA-MRSA in the highly populous Zone 5
has increased, but is still lower than that of PVL− CA-MRSA.
Rates of CA-MRSA in other regions that also contain areas of
high disadvantage have not increased as markedly as within the
state’s north. This suggests that a combination of socio-
behavioural and environmental factors may be reducing the abil-
ity of PVL+ CA-MRSA to proliferate within more temperate geo-
graphic locations within the state.
Climatic influences on MRSA SSTIs have previously been
explored [30], although a paucity of evidence exists. The data col-
lected by Sahoo et al. suggest a combination of temperature and
humidity; namely, average weekly maximum temperatures above
33 °C and an average weekly relative humidity between 55% and
78% was associated with an increase in S. aureus-associated
SSTIs [30]. Average maximum temperature and humidity data
across climate bands published by the Bureau of Meteorology sug-
gest that optimum conditions for colonisation and spread of
MRSA are present in northerly climate zones of the state for a
large proportion of the year.
Further work linking transmission to climatic factors is recom-
mended to better describe this phenomenon. Factors outside of
the presence of PVL-associated genes and the presence of high-
risk populations may help to explain the geographic differences
in prolific CA-MRSA clones, and could at least partially account
Table 3. Factors associated with a PVL+ CA-MRSA infection
aORa CI95
Sex
Female 1.00 Ref
Male 1.27 1.22 1.32
Climate zone
Zone 1 2.24 2.07 2.41
Zone 3 1.33 1.25 1.42
Zone 4 1.10 1.02 1.20
Zone 5 1.00 Ref
Age group
0–9 years 20.20 17.92 22.84
10–19 years 31.22 27.60 35.43
20–29 years 25.05 22.19 28.36
30–39 years 19.76 17.50 22.37
40–49 years 15.13 13.38 17.16
50–59 years 10.80 9.52 12.28
60–69 years 5.52 4.84 6.32
70–79 years 2.46 2.12 2.87
80+ years 1.00 Ref
aAdjusted for age group, sex, climate zone, IRSAD and year.
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for the apparent ecological niche that seemingly encourages the
transmission of some strains within a region, while limiting the
spread of others.
Limitations of this retrospective, population-based study
include the inability to account for changes in the healthcare pro-
vider behaviour over the 15-year study period, in particular the
propensity to send specimens for culture and typing. It is reason-
able to assert that a rapid rise of specific PVL+ isolates within a
region, causing SSTIs in increasing number and severity, raised
the profile of CA-MRSA among local clinicians and drove up test-
ing numbers to an extent.
The observed increases in PVL− CA-MRSA observed mainly
in the Kimberley region may, indeed, be largely driven by an
increased propensity to test for CA-MRSA. Increased testing,
however, should not have any impact on the proportion of PVL
+ isolates comprising the total number of specimens, suggesting
that the increase in PVL+ cases in regional WA is not entirely
an artefact of increased testing, but instead represents a true out-
break within the state.
Despite this limitation, the increased rates of PVL− disease,
combined with an almost 50% reduction in these clones propor-
tionally demonstrates that PVL+ clones have not replaced PVL−
clones, but rather added to the burden of disease within the state.
While information on individual PVL− clones is not available, the
relatively minor comparative increase in rates of these clones over-
all suggests that it is unlikely that one or more particular outbreak
clones were responsible for driving this, as was observed with PVL
+ clones.
An additional limitation was that Aboriginality was not avail-
able as an indicator for this dataset, prohibiting further investiga-
tion of this as a risk factor. In place of this variable, IRSAD was
used as a proxy measure, to account for the relative socio-
economic disadvantage prevalent in remote communities. After
controlling for IRSAD in the regression model, there were still
significantly increased proportions of CA-MRSA identified in
the northern zones.
Public health management of this current outbreak remains a
challenge. The suggested propensity for CA-MRSA, particularly
PVL+ clones, to spread in hotter and more humid areas, particu-
larly among vulnerable communities, suggests WA may expect
similar increases in incidence rates across a number of regions
in future. Countries with climatic conditions favourable for colon-
isation and spread of CA-MRSA should adopt proactive mitiga-
tion strategies, particularly in areas where vulnerable
populations reside.
Further work to evaluate the impact of this outbreak on the
healthcare system within affected regions could provide evidence
of the increased burden on individual patients that results from
severe SSTIs, and further quantify the economic impact to health-
care systems. Such evidence could be used as further justification
for increased prevention efforts, both to halt the current outbreak
and to prevent the emergence of virulent strains in future.
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